Alto Neuroscience (ANRO) Assets Average (2024 - 2026)
Alto Neuroscience (ANRO) posted Assets Average of $230.5 million for Q1 2026, up 38.97% sequentially from $165.8 million in Q4 2025, and up 31.9% YoY from $174.7 million in Q1 2025.
Alto Neuroscience (ANRO) Assets Average (2024 - 2026) Analysis & Trends
Alto Neuroscience has reported Assets Average for 3 years, with the latest figure at $230.5 million in Q1 2026.
- Quarterly Assets Average rose 31.9% year-over-year to $230.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230.5 million (up 31.9% YoY) and the FY2025 annual result came in at $181.1 million, up 37.12% from the prior year.
- Assets Average grew to $230.5 million in Q1 2026 per ANRO's latest filing, from $165.8 million in the prior quarter.
- Over five years, Assets Average peaked at $230.5 million in Q1 2026 and troughed at $148.3 million in Q1 2024.
- A 3-year average of $179.9 million and a median of $174.7 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average fell 21.62% in 2025, then soared 31.9% in 2026.
- Over 3 years, Assets Average stood at $184.6 million in 2024, then decreased by 10.15% to $165.8 million in 2025, then soared by 38.97% to $230.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $230.5 million, $165.8 million, and $152.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 265.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 265.16 Mn |
| Mar 31, 2026 | 230.47 Mn |
| Dec 31, 2025 | 165.85 Mn |
| Sep 30, 2025 | 152.44 Mn |
| Jun 30, 2025 | 164.90 Mn |
| Mar 31, 2025 | 174.73 Mn |
| Dec 31, 2024 | 184.58 Mn |
| Sep 30, 2024 | 194.48 Mn |
| Jun 30, 2024 | 203.64 Mn |
| Mar 31, 2024 | 148.28 Mn |